EXPLORE A TOPIC
Research and resources to help you take a closer look.
The resource library
6 resourcesA lack of cytotoxicity in fibroblast assays for TB-500 does not equate to organism-level safety. This article explains the limitations of in vitro cytotoxicity findings, the difference between cellular and systemic toxicity, and the need for broader safety evaluation, referencing recent analytical and biological studies.
This article explains the scientific concepts of limit of detection (LOD) and limit of quantification (LOQ) as applied to TB-500 peptide research. It distinguishes these analytical parameters, discusses their relevance in interpreting study abstracts, and highlights methodological limitations and uncertainties based on current evidence.
This article explains the distinct roles of specificity, precision, and recovery in the analytical validation of TB-500 (N-acetylated LKKTETQ) detection in equine plasma, based strictly on reported findings. It clarifies terminology, experimental context, and evidence limitations, and guides readers in interpreting such analytical abstracts.
A technical review of how experimental models and biological matrices influence TB-500 peptide analysis, metabolism, and interpretation of research findings. Distinguishes in-vitro, animal, and sample-specific results, highlighting methodological limitations and the importance of context in peptide research.
Detecting a TB-500 metabolite in biological samples confirms exposure and metabolic processing but does not, by itself, demonstrate any biological benefit. Evidence from analytical and in vitro studies shows that metabolite presence is distinct from proven therapeutic effects, especially in the absence of controlled human data. This article examines the research context, experimental findings, and limitations.
Explore TB-500 identity and metabolism studies, how the studied fragment differs from thymosin beta-4, and why laboratory findings do not prove human benefits.
